Exploration of acute toxicity effect of CKLF1-C19 on KM mice
  • Article
  • | |
  • Metrics
  • |
  • Reference [21]
  • |
  • Related
  • |
  • Cited by
  • | |
  • Comments
    Abstract:

    Objective To explore the acute toxicity effect of CKLF1-C19, a polypeptide of chemokine-like factor 1 (CKLF1), on the KM mice. Methods A total of 40 KM mice, half male and half female, were randomly divided into 2 groups. The mice in the experimental group were injected with CKLF1-C19 at a dose of 25 mL/kg (100 μg/mL, 1 mg/mL and 10 mg/mL) through the tail vein, and those in the control group received an equal volume of sterile saline solution. Changes in the body weight of the mice were recorded the day after treatment, and the general conditions of mice in the experimental group were observed closely and compared with the normal group. Then blood samples were taken from the abdominal aorta to measure liver and kidney function. Tissue samples of liver, kidney, spleen and lung were taken for histopathological examination by HE staining. Results In the maximum tolerance test, the mice of the two groups were in good condition, and their body weight was increased gradually, without significant difference between the experimental group and the control group (P > 0.05). There was no death within 14 days. The blood biochemical indexes of liver and kidney function showed no significant differences between the two groups (P > 0.05). The gross appearances of heart, liver, kidney, spleen and lung were normal in the two mouse groups, and the pathological examination with HE staining showed normal clear structure with no obvious changes in these organs of each group. Conclusions Our results demonstrate that CKLF1-C19 has no acute toxicity effect on mice.

    Reference
    [1] Han W, Lou Y, Tang J, et al. Molecular cloning and characterization of chemokine-like factor 1 (CKLF1), a novel human cytokine with unique structure and potential chemotactic activity [J]. Biochem J, 2001, 357: 127-135.
    [2] Wang Y, Zhang Y, Han W, et al. Two C-terminal peptides of human CKLF1 interact with chemokine receptor CCR4 [J]. Int J Biochem Cell Biol, 2008, 40(5): 909-919.
    [3] Wang Y, Zhang Y, Yang X, et al. Chemokine-like factor 1 is a functional ligand for CC chemokine receptor 4 (CCR4) [J]. Life Sci, 2006, 78(6): 614-621.
    [4] Tan Y, Ma D, Han W, et al. Chemokine-like factor 1, a novel human cytokine, contributes to the airway remodeling in asthma [C]. Abstract Book, 3rd Triennial World Asthma Meeting. Chicago, 2001.
    [5] 谭亚夏, 钟南山. 趋化素样因子1在支气管肺损伤与重建中的作用 [J]. 中华结核和呼吸杂志, 2002, 25(7): 433.
    [6] Tan Y, Han W, Chen Y, et al. Chemokine-like factor 1, a novel cytokine, contributes to airway damage, remodeling and pulmonary fibrosis [J]. Chin Med J (Engl), 2004, 117(8): 1123-1129.
    [7] Tian L, Li W, Wang J, et al. The CKLF1-C19 peptide attenuates allergic lung inflammation by inhibiting CCR3- and CCR4-mediated chemotaxis in a mouse model of asthma [J]. Allergy, 2011, 66(2): 287-297.
    [8] Zheng Y, Guo C, Zhang Y, et al. Alleviation of murine allergic rhinitis by C19, a C-terminal peptide of chemokine-like factor 1 (CKLF1) [J]. Int Immunopharmacol, 2011, 11(12): 2188-2193.
    [9] 俞发荣, 张诗爽, 张振南, 等. 玛咖提取物对小鼠毒性及免疫器官的影响 [J].中国实验动物学报, 2016, 24(3): 279-282.
    [10] 周立国. 药物毒理学 [M]. 第2版. 北京: 中国医药科技出版社, 2009: 131-148.
    [11] 贺银丽, 郭珣, 赵显莉, 等. PPARα转基因小鼠在药物毒性评价中的应用 [J]. 中国实验动物学报, 2015, 23(3): 316-320.
    [12] Pawankar R, Canonica GW, Holgate ST, et al. WAO White Book on Allergy Exacutive Summary: Update 2013 [Z]. World Allergy Organization, 2013.
    [13] 赵娟, 马晨丽, 兰元翎, 等. CKLF1拮抗肽C19在小鼠特应性皮炎中的作用研究 [J]. 临床和实验医学杂志, 2014, 13(21): 1748-1752.
    [14] 任进. 国际毒性病理学研究的新趋势新要求 [J]. 中国药理学与毒理学杂志, 2013, 27(3): 451.
    [15] 廖明阳. 与时俱进应对药物毒理学模式转变的机遇与挑战 [J]. 中国药理学与毒理学杂志, 2013, 27(3): 452.
    [16] 马璟, 李华. 纳米药物的安全性评价 [J]. 中国药理学与毒理学杂志, 2013, 27(3): 452-453.
    [17] 汪巨峰. 新药临床前心血管毒理学评价研究 [J]. 中国药理学与毒理学杂志, 2013, 27(3): 453.
    [18] 岑小波. 生物仿制药临床前安全研究与评价 [J]. 中国药理学与毒理学杂志, 2013, 27(3): 454.
    [19] To T, Stanojevic S, Moores G, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey [J]. BMC Public Health, 2012, 12: 204.
    [20] Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions [J]. Drug Discov Today, 2015, 20(1): 122-128.
    [21] 厉保秋. 多肽药物研究与开发 [M]. 第1版. 北京: 人民卫生出版社, 2011: 1-50.
    Related
    Cited by
Get Citation
Related Videos

Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:December 14,2016
  • Online: November 28,2017
Article QR Code